Global Markets Directs, Schistosomiasis - Pipeline Review, H2 2014, provides an overview of the Schistosomiasiss therapeutic pipeline.
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238878
This report provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238878
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Schistosomiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Schistosomiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Schistosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Schistosomiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Schistosomiasis Overview
Therapeutics Development
Pipeline Products for Schistosomiasis - Overview
Pipeline Products for Schistosomiasis - Comparative Analysis
Schistosomiasis - Therapeutics under Development by Companies
Schistosomiasis - Therapeutics under Investigation by Universities/Institutes
Schistosomiasis - Pipeline Products Glance
Early Stage Products
Schistosomiasis - Products under Development by Companies
Schistosomiasis - Products under Investigation by Universities/Institutes
Schistosomiasis - Companies Involved in Therapeutics Development
BioDiem Ltd
Concert Pharmaceuticals, Inc.
Kancera AB
LondonPharma Ltd
Schistosomiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BDM-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Praziquantel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
intestinal schistosomiasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Schistosomiasis - Recent Pipeline Updates
Schistosomiasis - Dormnt Projects
Schistosomiasis - Product Development Milestones
Featured News & Press Releases
Aug 23, 2013: BioDiem US patent for skin and wound infections
Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Schistosomiasis, H2 2014
Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Schistosomiasis - Pipeline by BioDiem Ltd, H2 2014
Schistosomiasis - Pipeline by Concert Pharmaceuticals, Inc., H2 2014
Schistosomiasis - Pipeline by Kancera AB, H2 2014
Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Schistosomiasis Therapeutics - Recent Pipeline Updates, H2 2014
Schistosomiasis - Dormant Projects, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
To Read the Complete Report with Toc Visit: http://www.marketresearchreports.biz/analysis/238878
This report provides comprehensive information on the therapeutic development for Schistosomiasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Schistosomiasis and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/238878
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Schistosomiasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Schistosomiasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Schistosomiasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Schistosomiasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Schistosomiasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Schistosomiasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Introduction
Global Markets Direct Report Coverage
Schistosomiasis Overview
Therapeutics Development
Pipeline Products for Schistosomiasis - Overview
Pipeline Products for Schistosomiasis - Comparative Analysis
Schistosomiasis - Therapeutics under Development by Companies
Schistosomiasis - Therapeutics under Investigation by Universities/Institutes
Schistosomiasis - Pipeline Products Glance
Early Stage Products
Schistosomiasis - Products under Development by Companies
Schistosomiasis - Products under Investigation by Universities/Institutes
Schistosomiasis - Companies Involved in Therapeutics Development
BioDiem Ltd
Concert Pharmaceuticals, Inc.
Kancera AB
LondonPharma Ltd
Schistosomiasis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
BDM-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Praziquantel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
intestinal schistosomiasis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Schistosomiasis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Schistosomiasis - Recent Pipeline Updates
Schistosomiasis - Dormnt Projects
Schistosomiasis - Product Development Milestones
Featured News & Press Releases
Aug 23, 2013: BioDiem US patent for skin and wound infections
Feb 08, 2013: BioDiem Progresses To Proof-Of-Concept Testing Of BDM-I Antimicrobial Effect Against Parasites
Nov 08, 2012: BioDiem Partners With Griffith University To Enhance Antimicrobial Drug BDM-I
Oct 18, 2012: BioDiem Reports Continued Progress In Development Of Antimicrobial BDM-I
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Schistosomiasis, H2 2014
Number of Products under Development for Schistosomiasis - Comparative Analysis, H2 2014
Number of Products under Development by Companies, H2 2014
Number of Products under Investigation by Universities/Institutes, H2 2014
Comparative Analysis by Early Stage Development, H2 2014
Products under Development by Companies, H2 2014
Products under Investigation by Universities/Institutes, H2 2014
Schistosomiasis - Pipeline by BioDiem Ltd, H2 2014
Schistosomiasis - Pipeline by Concert Pharmaceuticals, Inc., H2 2014
Schistosomiasis - Pipeline by Kancera AB, H2 2014
Schistosomiasis - Pipeline by LondonPharma Ltd, H2 2014
Assessment by Monotherapy Products, H2 2014
Number of Products by Stage and Target, H2 2014
Number of Products by Stage and Mechanism of Action, H2 2014
Number of Products by Stage and Route of Administration, H2 2014
Number of Products by Stage and Molecule Type, H2 2014
Schistosomiasis Therapeutics - Recent Pipeline Updates, H2 2014
Schistosomiasis - Dormant Projects, H2 2014
About us
MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Visit: http://www.prnewswire.com/news/marketresearchreports.biz
No comments:
Post a Comment